CA2891556A1 - Use of il-1 beta binding antibodies for treating peripheral arterial disease - Google Patents

Use of il-1 beta binding antibodies for treating peripheral arterial disease Download PDF

Info

Publication number
CA2891556A1
CA2891556A1 CA2891556A CA2891556A CA2891556A1 CA 2891556 A1 CA2891556 A1 CA 2891556A1 CA 2891556 A CA2891556 A CA 2891556A CA 2891556 A CA2891556 A CA 2891556A CA 2891556 A1 CA2891556 A1 CA 2891556A1
Authority
CA
Canada
Prior art keywords
beta
binding antibody
seq
functional fragment
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2891556A
Other languages
English (en)
French (fr)
Inventor
Mark Fishman
Tom Thuren
Shi Yin Foo
Craig BASSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2891556A1 publication Critical patent/CA2891556A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2891556A 2012-11-16 2013-11-14 Use of il-1 beta binding antibodies for treating peripheral arterial disease Abandoned CA2891556A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727334P 2012-11-16 2012-11-16
US61/727,334 2012-11-16
PCT/US2013/070042 WO2014078502A1 (en) 2012-11-16 2013-11-14 Use of il-1 beta binding antibodies for treating peripheral arterial disease

Publications (1)

Publication Number Publication Date
CA2891556A1 true CA2891556A1 (en) 2014-05-22

Family

ID=49679654

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2891556A Abandoned CA2891556A1 (en) 2012-11-16 2013-11-14 Use of il-1 beta binding antibodies for treating peripheral arterial disease

Country Status (6)

Country Link
US (4) US10000565B2 (enExample)
EP (1) EP2919811B1 (enExample)
JP (1) JP2016502526A (enExample)
AU (1) AU2013344796B2 (enExample)
CA (1) CA2891556A1 (enExample)
WO (1) WO2014078502A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180291097A1 (en) * 2015-06-04 2018-10-11 Craig Basson Use of il-1 beta binding antibodies to treat peripheral arterial disease
JP2018516931A (ja) 2015-06-04 2018-06-28 ノバルティス アーゲー 末梢動脈疾患を処置するためのｉｌ−１ベータ結合抗体の使用
TWI833685B (zh) 2015-07-31 2024-03-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 預測抗體之生物利用度之方法
CN108603188A (zh) * 2015-11-24 2018-09-28 联邦科学技术研究组织 在细胞培养物中产生病毒
EP3487584A1 (en) * 2016-07-21 2019-05-29 Novartis AG Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US20200315540A1 (en) 2016-12-14 2020-10-08 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
RU2020113234A (ru) * 2017-09-13 2021-10-13 Новартис Аг ПРИМЕНЕНИЕ АНТИТЕЛ, СВЯЗЫВАЮЩИХ IL-1β, ДЛЯ ЛЕЧЕНИЯ АЛКОГОЛЬНОГО ГЕПАТИТА
EP3852617B1 (en) * 2018-09-20 2025-09-10 SFJ Pharma X, Inc. Use of antibody fragments for reversing ticagrelor activity
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN112402359A (zh) * 2020-11-04 2021-02-26 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法
WO2026006472A2 (en) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Compositions of il-1r1 antibodies and methods of producing and using the same
WO2026003765A1 (en) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies
WO2026145640A1 (zh) * 2025-01-03 2026-07-09 长春金赛药业有限责任公司 一种抗IL-1β抗体的药物组合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
WO2008077145A2 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
WO2009120307A2 (en) 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
KR20110016959A (ko) * 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
AU2009289547A1 (en) * 2008-09-05 2010-03-11 Xoma (Us) Llc Methods for treating or preventing IL-1beta related diseases
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
NZ593905A (en) * 2009-01-29 2013-03-28 Abbott Lab Il-1 binding proteins
SG2014014534A (en) * 2009-05-29 2014-07-30 Xoma Technology Ltd CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF
AU2010306681A1 (en) 2009-10-15 2012-04-19 Abbvie Inc. IL-1 binding proteins
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
WO2013049278A1 (en) * 2011-09-30 2013-04-04 Novartis Ag USE OF IL-1 ß BINDING ANTIBODIES

Also Published As

Publication number Publication date
US20210317202A1 (en) 2021-10-14
JP2016502526A (ja) 2016-01-28
AU2013344796B2 (en) 2016-11-10
US20200148759A1 (en) 2020-05-14
US20160326243A1 (en) 2016-11-10
WO2014078502A1 (en) 2014-05-22
AU2013344796A1 (en) 2015-05-07
EP2919811B1 (en) 2018-12-26
EP2919811A1 (en) 2015-09-23
US20180258166A1 (en) 2018-09-13
US10000565B2 (en) 2018-06-19

Similar Documents

Publication Publication Date Title
AU2013344796B2 (en) Use of IL-1 beta binding antibodies for treating peripheral arterial disease
US20230293683A1 (en) Methods of treating ankylosing spondylitis using il-17 antagonists
CA2849466C (en) Use of il-1.beta. binding antibodies
US20230265182A1 (en) Use of il-1 beta binding antibodies to treat peripheral arterial disease
JP2017510627A (ja) 多発性硬化症の併用治療
US20230331834A1 (en) Method of treating tendinopathy using interleukin-17 (il-17)
WO2015083120A1 (en) USE OF IL-1β BINDING ANTIBODIES
JP2025516723A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法
US20180291097A1 (en) Use of il-1 beta binding antibodies to treat peripheral arterial disease
RU2806304C1 (ru) Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181113

FZDE Discontinued

Effective date: 20210831